The Use of the Polymerase Chain Reaction to Predict for Subsequent Relapse in Unrelated Marrow Transplantation for Chronic Myelogenous Leukemia

References

• Roth M S, Antin J H, Bingham E L, Ginsburg D. Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplantation for chronic myelogenous leukemia. Blood 1989; 74: 882
   PubMed Web of Science ®Google Scholar
• Roth M S, Antin J H, Ash R, Terry V H, Gotlieb M, Silver S M, Ginsburg D. Prognostic significant of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992; 79: 276
   PubMed Web of Science ®Google Scholar
• Delage R, Soiffer R J, Dear K, Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 1991; 78: 2759
   PubMed Web of Science ®Google Scholar
• Hughes T P, Morgan G J, Martiat P, Goldman J M. Detection of residual leukemia after bone marrow transplantation for chronic myeloid leukemia: Role of polymerase chain in predicting relapse. Blood 1991; 77: 874
   PubMed Web of Science ®Google Scholar
• Miyamura K, Barrett A J, Kodera Y, Saito H. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: A review of recent results. Bone Marrow Transplantation 1994; 14: 201
   PubMed Web of Science ®Google Scholar
• Cross N C, Feng L, Chase A, Bungey J, Hughes T P, Goldman J M. Competitive polymerase chain reaction to estimate the number of bcr-abl transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929
   PubMed Web of Science ®Google Scholar
• Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukemia. Lancet 1993; 341: 275
   PubMed Web of Science ®Google Scholar
• Thompson J D, Brodsky I, Yunis J J. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 1992; 79: 1629
   PubMed Web of Science ®Google Scholar
• Goldman J M, Gale R P, Horowitz M M, Biggs J C, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Int Med 1988; 108: 806
   PubMed Web of Science ®Google Scholar
• Mitsuyasu R T, Champlin R E, Gale R P, Ho W G, et al. Treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for the prevention of graft-ver-sus-host disease: A prospective, randomized, double-blind trial. Ann Intern Med 1986; 105: 20
   PubMed Web of Science ®Google Scholar
• Marmont A M, Horowitz M M, Gale R P, Sobocinski K, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120
   PubMed Web of Science ®Google Scholar
• Horowitz M M, Gale R P, Sondel P M, Goldman J M, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555
   PubMed Web of Science ®Google Scholar
• Hessner M J, Endean D J, Casper J T, Horowitz M M, Keever-Taylor C A, Roth M, Flomenberg N, Drobyski W R. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T cell depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995; 86: 3987
   PubMed Web of Science ®Google Scholar
• Drobyski W R, Ash R C, Casper J T, McAuliffe T, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 1980
   PubMed Web of Science ®Google Scholar
• Waid T H, Lucas B A, Amlot P, Janossy G, Yacoub M, Cammisuli S, Jezek D, Rhoades J, Brown S, Thompson J S. TIOB9. 1A-31 anti-T cell monoclonal antibody: Preclinical studies and clinical treatment of solid organ allograft rejection. American Journal of Kidney Diseases 1989; 14(5 Suppl 2)61
   PubMed Web of Science ®Google Scholar
• Hessner M J, Roth M S, Drobyski W R, Baxter-Lowe L A. Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. Genetic Analysis, Techniques and Applications 1994; 11: 90
   PubMedGoogle Scholar
• Radich J P, Gehly G, Gooley T, Bryant E, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia. Results and implications in 346 patients. Blood 1995; 85: 2632
   PubMed Web of Science ®Google Scholar
• Higano C S, Raskind W H, Singer J W. Use of Alpha interferon for treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 1992; 80: 1437
   PubMed Web of Science ®Google Scholar
• Higano C S, Chielens D, Raskind W, Bryant E, et al. Use of α-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997; 90: 2549
   PubMed Web of Science ®Google Scholar
• Kolb H J, Mittermuller J, Clemm C H, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns. Donor leukocyte infusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462
   PubMed Web of Science ®Google Scholar
• Kolb H J, Schattenberg A, Goldman J M, Hertenstein B, et al. Graft-versus-leukemia effect of donor lymphocyte infusions in marrow grafted patients. Blood 1995; 86: 2041
   PubMed Web of Science ®Google Scholar
• Drobyski W R, Keever C A, Roth M S, Koethe S, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310
   PubMed Web of Science ®Google Scholar
• Collins Shpilberg R. O, Drobyski W, Porter D, et al. Donor Leukocyte Infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology 1997; 15: 433
   PubMed Web of Science ®Google Scholar
• Arcese W, Goldman J M, D'Arcangelo E, Schattenberg A, et al. Outcome of patients with relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 1993; 82: 3211
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos E B, Carabasi M H, Reich L, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261
   PubMed Web of Science ®Google Scholar
• McGlave P, Kollman C, Shu X O, Anasetti C, Nademanee A, Champlin R, Antin J, Kernan N, King R. The first 1000 unrelated donor transplants for CML: Lessons from the National Marrow Donor Program experience. Blood 1996; 88: 483a
   Web of Science ®Google Scholar
• Kernan A, Bartsch G, Ash R C, Beatty P G, Champlin R, Filipovich A, Gajewski J, Hansen J A, Henslee-Downey J, McCullough J, McGlave P, Perkins H A, Phillips G L, Sanders J, Stroncek D, Thomas E D, Blume K G. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New England Journal of Medicine 1993; 328: 593
   PubMed Web of Science ®Google Scholar